Comment by elamje
19 days ago
Not arguing on broken internal pricing dynamics that are skewed by all sorts of gov programs and payors.
It’s about external, global pricing dynamics. The site clearly isn’t going to be able to give clean payor/pbm/gov subsidized pricing tables - that is almost an impossible exercise in our system.
What the agreement does accomplish is saying Americans will not pay $1150/mo while EU pays $400/mo while Argentina pays $120/mo.
It guarantees drugs will be greater than or equal to US pricing abroad which effectively forces pharma to find deeper profits outside of the US, or lower prices for all countries to acquire demand.
That is extremely effective. Now it’s up to a really complex group of people to figure out what that means inside our weird system of pharma/pbm/rebates/insurance/medicare.
But that’s not what trumprx is aiming to solve for right?
> But that’s not what trumprx is aiming to solve for right?
Correct
> What the agreement does [...]
This is hypothetical and does not exist. It also is not going to happen, politically, because drug companies are currently expecting to charge US prices in the US, while charging lower, non-US prices outside the US.
> That is extremely effective
This is hypothetical—and, as I've said, the attempt that the Inflation Reduction Act made toward this was watered down by an executive order. To be fair, the negotiation mechanism is still in place, and its existence must be influencing drug pricing already.